Edition:
United Kingdom

BeyondSpring Reports Quarterly Loss Per Share $0.54


Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - BeyondSpring Inc ::BEYONDSPRING PROVIDES OPERATIONAL UPDATE AND SECOND-QUARTER 2018 FINANCIAL RESULTS.BEYONDSPRING - REPORTED TOP LINE POSITIVE EFFICACY AND SAFETY DATA FROM PHASE 2 STUDY 106 EVALUATING PLINABULIN IN COMBINATION WITH NEULASTA FOR CIN PREVENTION.BEYONDSPRING INC - ON TRACK TO REPORT INTERIM DATA FROM PHASE 3 STUDY 105 IN 4Q 2018.BEYONDSPRING INC QUARTERLY LOSS PER SHARE $0.54.BEYONDSPRING INC - ON TRACK TO SUBMIT NDA TO CHINA FOOD AND DRUG ADMINISTRATION (CFDA) FOR CIN IN LATE 2018 / EARLY 2019.BEYONDSPRING - ON TRACK TO REPORT INTERIM DATA FROM PHASE 3 STUDY 103 IN EARLY 2019, SUBMIT NDA TO CFDA FOR NON-SMALL CELL LUNG CANCER IN H1 2019. 

Company Quote

16.32
-0.65 -3.83%
22 Aug 2019